Cullen Frost Bankers Inc. increased its position in shares of Illumina Inc. (NASDAQ:ILMN) by 1.1% during the second quarter, Holdings Channel reports. The institutional investor owned 6,770 shares of the life sciences company’s stock after buying an additional 75 shares during the period. Cullen Frost Bankers Inc.’s holdings in Illumina were worth $951,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Physicians Financial Services Inc. boosted its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the last quarter. Checchi Capital Advisers LLC boosted its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares during the last quarter. IFP Advisors Inc boosted its stake in Illumina by 215.6% in the first quarter. IFP Advisors Inc now owns 1,133 shares of the life sciences company’s stock worth $184,000 after buying an additional 774 shares during the last quarter. Simonbaker & Partners LLC acquired a new stake in Illumina during the first quarter worth $243,000. Finally, First Manhattan Co. boosted its stake in Illumina by 90,000.0% in the second quarter. First Manhattan Co. now owns 1,802 shares of the life sciences company’s stock worth $252,000 after buying an additional 1,800 shares during the last quarter. 95.22% of the stock is owned by institutional investors and hedge funds.
Illumina Inc. (NASDAQ:ILMN) traded up 0.35% on Wednesday, reaching $180.98. 662,283 shares of the company were exchanged. The stock has a market capitalization of $26.53 billion, a P/E ratio of 61.98 and a beta of 0.73. Illumina Inc. has a 12-month low of $127.10 and a 12-month high of $196.47. The company’s 50-day moving average price is $172.01 and its 200-day moving average price is $154.77.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.13. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The company had revenue of $600 million for the quarter, compared to analyst estimates of $31.91 million. During the same period in the prior year, the firm posted $0.80 EPS. The company’s quarterly revenue was up 11.3% on a year-over-year basis. Equities research analysts anticipate that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.
A number of research firms recently weighed in on ILMN. Zacks Investment Research raised shares of Illumina from a “sell” rating to a “hold” rating in a research note on Monday, July 4th. CL King cut shares of Illumina from a “buy” rating to a “neutral” rating in a research note on Monday, August 22nd. Piper Jaffray Cos. reissued an “overweight” rating and issued a $161.00 target price on shares of Illumina in a research note on Friday, July 15th. Vetr cut shares of Illumina from a “buy” rating to a “sell” rating and set a $142.96 target price on the stock. in a research note on Tuesday, July 26th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $165.00 target price on shares of Illumina in a research note on Thursday, June 2nd. Two equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $163.07.
In other news, Director Robert S. Epstein sold 300 shares of the company’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $174.29, for a total value of $52,287.00. Following the sale, the director now directly owns 6,924 shares of the company’s stock, valued at approximately $1,206,783.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction on Tuesday, August 23rd. The shares were sold at an average price of $172.99, for a total transaction of $3,459,800.00. Following the completion of the sale, the director now directly owns 508,061 shares in the company, valued at $87,889,472.39. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.